All In Biotech

Drug Trial Radar · NCT03258931

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

214

Actual

Start

Aug 15, 2018

Primary completion

Apr 6, 2026

Study completion Apr 6, 2026

Sponsor

Lead sponsor
Arog Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.

Conditions

  • Newly Diagnosed FLT3 Mutated AML

Interventions

  • CrenolanibDrug

    Crenolanib will be administered orally

  • MidostaurinDrug

    Midostaurin will be administered orally

  • CytarabineDrug

    100 mg/m² IV continuous infusion over 24 hours

  • DuanorubicinDrug

    90 mg/m2 IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: 5 years

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • US Davis Health

    Sacramento, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • Rush Medical Center

    Chicago, Illinois

  • University of Illinois at Chicago

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deacnss Medical Center Oncology

    Boston, Massachusetts

  • Dana-Farber Cancer Insitute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Roswell Park

    Buffalo, New York

  • New York University

    New York, New York

  • Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Cornell University

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • University of Rochester Medical Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • The UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Wake Forest Baptist Health, Section on Hematology & Oncology

    Winston-Salem, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • University of Virginia Health System

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.